Publications

Click HERE for Sara's PubMed
  1. Chen, J.G., Liu, X., Munshi, M., Xu, L., Tsakmaklis, N., Demos, M.G., Kofides, A., Guerrera, M.L., Chan, G.G., Patterson, C.J., Meid, K., Gustine, J., Dubeau, T., Severns, P., Castillo, J.J., Hunter, Z.R., Wang, J., Buhrlage, S.J., Gray, N.S., Treon, S.P., Yang, G., 2018. BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism. Blood 131, 2047–2059. https://doi.org/10.1182/blood-2017-10-811752
  2. Stolte, B., Iniguez, A.B., Dharia, N.V., Robichaud, A.L., Conway, A.S., Morgan, A.M., Alexe, G., Schauer, N.J., Liu, X., Bird, G.H., Tsherniak, A., Vazquez, F., Buhrlage, S.J., Walensky, L.D., Stegmaier, K., 2018. Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma. J. Exp. Med. https://doi.org/10.1084/jem.20171066
  3. Lamberto, I., Liu, X., Seo, H.-S., Schauer, N.J., Iacob, R.E., Hu, W., Das, D., Mikhailova, T., Weisberg, E.L., Engen, J.R., Anderson, K.C., Chauhan, D., Dhe-Paganon, S., Buhrlage, S.J., 2017. Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7. Cell Chem Biol 24, 1490-1500.e11. https://doi.org/10.1016/j.chembiol.2017.09.003
  4. LaRochelle, J.R., Fodor, M., Ellegast, J.M., Liu, X., Vemulapalli, V., Mohseni, M., Stams, T., Buhrlage, S.J., Stegmaier, K., LaMarche, M.J., Acker, M.G., Blacklow, S.C., 2017a. Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2. Bioorg. Med. Chem. 25, 6479–6485. https://doi.org/10.1016/j.bmc.2017.10.025
  5. LaRochelle, J.R., Fodor, M., Ellegast, J.M., Liu, X., Vemulapalli, V., Mohseni, M., Stams, T., Buhrlage, S.J., Stegmaier, K., LaMarche, M.J., Acker, M.G., Blacklow, S.C., 2017b. Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2. Bioorganic & Medicinal Chemistry 25, 6479–6485. https://doi.org/10.1016/j.bmc.2017.10.025
  6. Liu, X., Hunter, Z.R., Xu, L., Chen, J., Chen, J.G., Tsakmaklis, N., Patterson, C.J., Castillo, J.J., Buhrlage, S., Gray, N., Treon, S.P., Yang, G., 2017. Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia. Br. J. Haematol. 177, 808–813. https://doi.org/10.1111/bjh.14103
  7. Paolella, B.R., Gibson, W.J., Urbanski, L.M., Alberta, J.A., Zack, T.I., Bandopadhayay, P., Nichols, C.A., Agarwalla, P.K., Brown, M.S., Lamothe, R., Yu, Y., Choi, P.S., Obeng, E.A., Heckl, D., Wei, G., Wang, B., Tsherniak, A., Vazquez, F., Weir, B.A., Root, D.E., Cowley, G.S., Buhrlage, S.J., Stiles, C.D., Ebert, B.L., Hahn, W.C., Reed, R., Beroukhim, R., 2017. Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability. Elife 6. https://doi.org/10.7554/eLife.23268
  8. Sun, Y., Alberta, J.A., Pilarz, C., Calligaris, D., Chadwick, E.J., Ramkissoon, S.H., Ramkissoon, L.A., Garcia, V.M., Mazzola, E., Goumnerova, L., Kane, M., Yao, Z., Kieran, M.W., Ligon, K.L., Hahn, W.C., Garraway, L.A., Rosen, N., Gray, N.S., Agar, N.Y., Buhrlage, S.J., Segal, R.A., Stiles, C.D., 2017. A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro-oncology 19, 774–785. https://doi.org/10.1093/neuonc/now261
  9. Wang, L., Qiao, Q., Ferrao, R., Shen, C., Hatcher, J.M., Buhrlage, S.J., Gray, N.S., Wu, H., 2017. Crystal structure of human IRAK1. Proc. Natl. Acad. Sci. U.S.A. 114, 13507–13512. https://doi.org/10.1073/pnas.1714386114
  10. Weisberg, E.L., Puissant, A., Stone, R., Sattler, M., Buhrlage, S.J., Yang, J., Manley, P.W., Meng, C., Buonopane, M., Daley, J.F., Lazo, S., Wright, R., Weinstock, D.M., Christie, A.L., Stegmaier, K., Griffin, J.D., 2017a. Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget 8, 52026–52044. https://doi.org/10.18632/oncotarget.19036
  11. Weisberg, E.L., Schauer, N.J., Yang, J., Lamberto, I., Doherty, L., Bhatt, S., Nonami, A., Meng, C., Letai, A., Wright, R., Tiv, H., Gokhale, P.C., Ritorto, M.S., De Cesare, V., Trost, M., Christodoulou, A., Christie, A., Weinstock, D.M., Adamia, S., Stone, R., Chauhan, D., Anderson, K.C., Seo, H.-S., Dhe-Paganon, S., Sattler, M., Gray, N.S., Griffin, J.D., Buhrlage, S.J., 2017b. Inhibition of USP10 induces degradation of oncogenic FLT3. Nat. Chem. Biol. 13, 1207–1215. https://doi.org/10.1038/nchembio.2486
  12. Matthews, J.M., Bhatt, S., Patricelli, M.P., Nomanbhoy, T.K., Jiang, X., Natkunam, Y., Gentles, A.J., Martinez, E., Zhu, D., Chapman, J.R., Cortizas, E., Shyam, R., Chinichian, S., Advani, R., Tan, L., Zhang, J., Choi, H.G., Tibshirani, R., Buhrlage, S.J., Gratzinger, D., Verdun, R., Gray, N.S., Lossos, I.S., 2016. Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma. Blood 128, 239–248. https://doi.org/10.1182/blood-2016-02-696856
  13. Nishikawa, J.L., Boeszoermenyi, A., Vale-Silva, L.A., Torelli, R., Posteraro, B., Sohn, Y.-J., Ji, F., Gelev, V., Sanglard, D., Sanguinetti, M., Sadreyev, R.I., Mukherjee, G., Bhyravabhotla, J., Buhrlage, S.J., Gray, N.S., Wagner, G., Näär, A.M., Arthanari, H., 2016. Inhibiting fungal multidrug resistance by disrupting an activator-Mediator interaction. Nature 530, 485–489. https://doi.org/10.1038/nature16963
  14. Yang, G., Buhrlage, S.J., Tan, L., Liu, X., Chen, J., Xu, L., Tsakmaklis, N., Chen, J.G., Patterson, C.J., Brown, J.R., Castillo, J.J., Zhang, W., Zhang, X., Liu, S., Cohen, P., Hunter, Z.R., Gray, N., Treon, S.P., 2016. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood 127, 3237–3252. https://doi.org/10.1182/blood-2016-01-695098
  15. Pery, E., Sheehy, A., Nebane, N.M., Brazier, A.J., Misra, V., Rajendran, K.S., Buhrlage, S.J., Mankowski, M.K., Rasmussen, L., White, E.L., Ptak, R.G., Gabuzda, D., 2015. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein. J. Biol. Chem. 290, 10504–10517. https://doi.org/10.1074/jbc.M114.626903
  16. Tan, L., Nomanbhoy, T., Gurbani, D., Patricelli, M., Hunter, J., Geng, J., Herhaus, L., Zhang, J., Pauls, E., Ham, Y., Choi, H.G., Xie, T., Deng, X., Buhrlage, S.J., Sim, T., Cohen, P., Sapkota, G., Westover, K.D., Gray, N.S., 2015. Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J. Med. Chem. 58, 183–196. https://doi.org/10.1021/jm500480k​